All In Biotech

Drug Trial Radar · NCT06943820

AK129 Combination Therapy for Advanced Solid Tumors

A Phase Ib/II Study of Anti-PD-1/LAG-3 Bispecific Antibody AK129 Combinations in Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jun 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 230 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

230

Planned (sponsor's estimate)

Start

May 21, 2025

Primary completion

Dec 2026

Study completion May 2028

Sponsor

Lead sponsor
AkesoIndustry
Sponsor type
Industry
First posted
Apr 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open, multicenter phase Ib/II clinical study. The goal of this study is to confirm the Phase II recommended dose (RP2D) of AK129 combinations for advanced solid tumors and evaluate the safety and efficacy of AK129 combinations for non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), colorectal adenocarcinoma (CRC), and other advanced solid tumors.

Conditions

  • Non-small Cell Lung Cancer Stage IIIB/IV
  • Head and Neck Squamous Cell Carcinoma (HNSCC)
  • Colorectal Adenocarcinoma
  • Advanced Solid Tumors

Interventions

  • AK129(dose 1)Drug

    IV infusion

  • PemetrexedDrug

    IV infusion;500mg/m2

  • PaclitaxelDrug

    IV infusion;175mg/m2

  • CarboplatinDrug

    IV infusion;AUC 5

  • AK129(dose 2)Drug

    IV infusion

  • DocetaxelDrug

    IV infusion;75mg/m2

  • Cis-platinumDrug

    IV infusion;100 mg/m2

  • 5-FU (5-fluorouracil)Drug

    IV infusion;1000 mg/m2

  • CetuximabDrug

    IV infusion;400mg/m2/ 250mg/m2

  • PaclitaxelDrug

    IV infusion;80mg/m2

  • DocetaxelDrug

    IV infusion;35mg/m2

  • ChemotherapyDrug

    IV infusion

  • AK129(RP2D)Drug

    IV infusion

  • PenpulimabDrug

    IV infusion;200mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency and severity of adverse events (AEs) ,Clinically significant abnormal laboratory resultsTime frame: Up to approximately 2 years
  2. Overall Response Rate (ORR)Time frame: Up to approximately 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Liaoning Cancer Hospital

    Shenyang, Liaoning, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.